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Abstract: The growth factors BDNF and GDNF are gaining more and more attention as modulators of 
synaptic transmission in the mature central nervous system (CNS). The two molecules undergo a regulated 
secretion in neurons and may be anterogradely transported to terminals where they can positively or 
negatively modulate fast synaptic transmission. There is today a wide consen- sus on the role of BDNF as a 
pro-nociceptive modulator, as the neurotrophin has an important part in the initiation and maintenance of 
inflammatory, chronic, and/or neuropathic pain at the peripheral and central level. At the spinal level, 
BDNF intervenes in the regulation of chloride equilibrium potential, decreases the excitatory synaptic drive 
to inhibitory neurons, with complex changes in GABAergic/glycinergic synaptic transmission, and 
increases excitatory transmission in the superficial dorsal horn. Differently from BDNF, the role of GDNF 
still remains to be unraveled in full. This review resumes the current literature on the interplay between 
BDNF and GDNF in the regulation of nociceptive neurotransmission in the superficial dorsal horn of the 
spinal cord. We will first discuss the circuitries involved in such a regulation, as well as the reciprocal 
interactions between the two factors in nociceptive pathways. The development of small molecules 
specifically targeting      BDNF, GDNF and/or downstream effectors is opening new perspectives for 
investigating these neurotrophic factors as modulators of nociceptive transmission and chronic pain. 
Therefore, we will finally consider the molecules of (potential) pharmacological relevance for tackling 
normal and pathological pain. 
 




Neurotrophic factors (NFs) are a large and heterogeneous group of molecules supporting the growth, survival, 
and differentiation of developing and mature neurons. However, besides their “classical” trophic activity, NFs also 
act as neuronal modulators, affecting synaptic plasticity and neuronal endeavor [1]. Several NFs have received 
particular attention as modulators of nociception and players in the mala daptive changes leading to chronic pain 
under pathological conditions [2, 3]. Initial studies on the intervention of NFs in the modulation of the nerve 
pathways that convey pain-relat ed information to the brain have mainly focused on the role of nerve growth factor 
(NGF) in nociception and led to the development of novel pharmacological approaches to treat certain altered pain 
conditions [4]. More recently, the brain-derived neurotrophic factor (BDNF) [5] and the glial cell line-derived 
neurotrophic factor (GDNF) [6] have gained increasing attention as pain modulators. The reasons for such an 
interest are that the two factors and their receptors are ex pressed by the nociceptors, and the former likely play a role 
in the sensitization processes leading to chronic pain. However, the anatomical localization and the effects on 
neuronal activity induced by BDNF and GDNF are different, thus suggesting a dissimilar contribution to the 
processing of nociceptive stimuli. 
In this review, we will reconsider the state of art roles played by BDNF and GDNF in the control of nociceptive 
transmission and in the maladaptive changes that occur in pain pathological conditions. We will pay particular 
attention to the putative interactions and complementarities between the two molecules and, eventually, to the 
pharmacological strategies that may derive from this knowledge. 
2. NEUROTROPHIC FACTOR FAMILIES AND THEIR RECEPTORS: AN OVERVIEW 
NFs belong to three main families: the neurotrophin (NT) family, the GDNF ligand (GFL) family and the 
 
ciliary neurotrophic factor (CNTF) family. Here, we will focus on the NT and GFL families, which include BDNF 
and GDNF, respectively. There are two reasons for this choice. First, dur ing development, NTs and GFLs promote 
the differentiation and survival of the primary sensory neurons [7-11]. Second, in adulthood, they intervene in the 
regulation of the functional properties of these neurons, particularly in the modulation of their synaptic activity [5, 
6, 12, 13]. 
 
2.1. The Neurotrophin Family 
NGF, BDNF, neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5) compose the NT family. NTs share 
numerous commonalities: first, they all express extensive structural homologies in both genes and proteins [14]; 
second, the encoding genes contain a signal sequence and a prodomain; hence NTs are synthesized as pro-NTs, 
which need to be subsequently proteolyzed to obtain the functional ly active mature molecule; third, NT molecules 
are typically released as homodimers, which is the required configuration for binding to their respective receptors. 
NTs activate two different families of membrane receptors: a pan-NT receptor, known as p75
NTR
, and a group of 
tyrosine kinases receptors, collectively known as Trk receptors (for review [15, 16]). 
p75
NTR
 is a member of the tumor necrosis factor superfamily. It consists of an extracellular domain with four 
cysteine-rich motifs and an intracellular domain (including a “death domain”) acting on a pool of cytoplasmatic 
proteins. The receptor expression level in the peripheral and central nervous system decreases with the progression 
of the development, but typically increases following injury [17]. p75
NTR
 lacks an intrinsic catalytic activity, 
however, it can interact with other NT receptors (i.e., Trk receptors), as well as with sortilin and Nogo, to produce a 
broad spectrum of downstream effects [17]. 
Both NT and pro-NT dimers activate p75
NTR
, although with opposing effects [18]. Specifically, pro-NTs bind 
p75
NTR
 with high affinity and, in combination with the co-receptor sortilin, induce apoptosis or inhibit axonal growth 
[19]. This “death pathway” is intracellularly mediated by JNK kinases, which, in turn, cause cell death via the p53 
and Bax pro-apoptotic pathways [18]. Unlike pro-NTs, mature NTs exhibit a low affinity for p75
NTR
 and promote 
neuronal survival and differentiation [14, 20]. This “life pathway” seems largely mediated via the interaction 
between p75
NTR
 and the Trk receptors, i.e. by increasing the affinity of the mature NTs for the Trks [21](see below). 
Each mature member of the NT family binds with high affinity to a specific Trk receptor: NGF preferentially 
activates TrkA, BDNF and NT4/5 bind TrkB, and NT3 is associated with TrkC, but it is also a low-affinity agonist 
for TrkA and TrkB [22]. Trk receptors have an extracellular domain consisting of a cysteine-rich cluster, three 
leucine-rich repeats, another cysteine-rich cluster, two immunoglobulin-like domains, and an intracellular domain 
that possesses tyrosine kinase activity [14]. NTs binding induces Trk receptor dimerization, followed by 
phosphorylation of the cytoplasmic tyrosine residues, which, in turn, initiates the activation of downstream 
effectors [22]. Interestingly, Trk receptors are also active in the absence of NTs. Namely, they can be trans-
activated via a signaling pathway triggered by several G protein-coupled receptors (GPCR [14, 23]). The adenosine 
receptor A2A was firstly proposed to trans-activate TrkB receptors via G protein-dependent activation of Src kinases 
[24]. Subsequently, other GPCR neuromodulators were shown to induce Trk transactivation, such as the pituitary 
adenylate cyclase-activating polypeptide receptor (PACAP [23],), the angiotensin receptor type 2 [25], and the low-
density lipoprotein receptor-related protein-1 [26]. Tyrosine kinase activity can also be induced by mechanisms other 
than those mediated by GPCRs, for instance, by the epidermal growth factor receptor [27], or zinc, which is co-
released with glutamate at excitatory synapses [28]. 
Trk receptor activation is associated with three major signaling pathways: the Ras/mitogen-activated protein 
kinase (MAPK) pathway; the phosphatidylinositol-3-kinase (PI3K)/Akt pathway, and the phospholipase C-γ 
(PLCγ)/diacylglycerol (DAG)/protein kinase C (PKC) pathway [14, 29]. All these pathways are involved in cell 
survival and differentiation, but also in the modulation of neuronal activity (i.e., acting on ion channels and ion 
transporters) and in the regulation of neuronal plasticity [14, 16, 22]. PLCγ is then thought to play a major role in 
synaptic plasticity through inositol-3-phosphate release and Ca
2+
 mobilization from intracellular stores. 
To add another level of complexity, different splicing variants exist in each group of Trk receptors. Besides the 
“classical” full-length forms, splicing generates TrkB and TrkC isoforms that miss the tyrosine kinase domain and 
are often referred to as truncated receptor variants [30]. Although the role of these isoforms is still poorly 
understood, yet different studies have demonstrated that they are not inactive, as originally thought, but can evoke 
Ca
2+
 transients and trigger intracellular signals. Interestingly, a growing number of evidence indicates that signals 
from truncated Trk isoforms typically counteract the function of the respective full-length receptors, for instance, 
by inhibiting dimerization or by disrupting intracellular responses [31-35]. 
 
2.2. The GDNF Ligand Family 
The members of the GFL family, GDNF, neurturin, artemin and persephin, are structurally related to the 
 
 
transforming growth factor β (TGF-β) superfamily [36, 37]. Each member of the family is translated as a pre-pro-
precursor protein, which is subsequently cleaved to generate an active form [38, 39]. GFLs signal through a 
multicompetent recep tor complex comprising the tyrosine kinase transmembrane receptor Ret and a high-affinity 
ligand-binding glycosylphos- phatidylinositol (GPI)-anchored co-receptor referred to as GFRα [37]. Ret is a 
tyrosine kinase receptor constituted by an extracellular domain containing several cadherin-like repeats, a 
hydrophobic transmembrane domain, and an intracellular tyrosine kinase domain [40]. For the ligand to activate 
RET, it must bind first to the appropriate GFRα co-receptor. Each member of the GFL family matches with a 
specific GFRα isoform characterized by a distinct structure of the cysteine-rich repeats in the ligand-binding 
domains [37]. Namely, GDNF preferentially binds to GFRα1, neurturin to GFRα2, artemin to GFRα3 and persephin 
to GFRα4 [36]. Like NTs, also GFLs are released as homodimers, each binding two GFRα receptors that, in turn, 
induce Ret dimeriza- tion, thus conserving a 2:2:2 stoichiometry [41]. Ret dimers activate downstream 
intracellular pathways through their cy- tosolic tyrosine kinase domain. The interaction between GFLs, GFRα and 
Ret is favored by glycosaminoglycans, such as heparan sulphate, as the lack of these molecules is sufficient to 
abolish the survival and axonal growth effects of GDNF [42, 43]. Moreover, receptor/co-receptor interaction 
mainly occurs within sphingolipid- and cholesterol-rich membrane microdomains, known as lipid rafts, in which 
GFRsα are confined [44]. Therefore, the disruption of Ret localization in lipid rafts significantly weakens the 
associated intracellular signals [44]. GFRα-Ret activation mainly signals through Ras/MAPK, phosphatidylinositol-
3 kinase (PI3K)/Akt and PLCγ, which play a key role in neurite outgrowth and cell survival in the nervous system 
[45-47]. 
Consistently with a broader expression of GFRα than Ret in neurons, GFLs can also transduce through GFRα 
in a Ret-independent pathway [47, 48]. This was clearly demonstrated in Ret-deficient cell lines, in which GFRα-
mediated signals activate the Src-like kinase that phosphorylates the cAMP response element-binding protein 
(CREB) and induces c-fos expression and cell survival [48]. A special role in the activation of the Ret-independent 
pathway is played by the neural cell adhesion molecule (NCAM). Actually, NCAM acts as an alternative signaling 
pathway for GFLs, at the point that GFRα-NCAM, GDNF-NCAM and GDNF-GFRα-NCAM may differentially 
transduce various intracellular pathways (vertical signaling) or engage other molecules at the cell membrane 
(horizontal signaling) [46, 47, 49]. 
3. LOCALIZATION OF BDNF AND GDNF AND THEIR RECEPTORS IN NOCICEPTIVE 
PATHWAYS 
Spinal nociceptive pathways, in their most simple configuration, consist of a chain of three neurons: a primary 
senso- ry neuron, or nociceptor, located in dorsal root ganglia (DRGs), a secondary neuron in the spinal cord dorsal 
horn, and a third neuron in the ventroposterolateral nucleus of the thalamus, which eventually transmits the 
nociceptive information to the somatosensory cortex. An analogue chain of neurons conveys nociceptive stimuli 
from the head and the initial part of the neck along the trigeminal pathway. 
BDNF, GDNF and their receptors have been consistently described in these pathways, and particularly in 
DRGs and in spinal dorsal horn neurons (see for review [5, 6] and (Fig. 1). Understanding the anatomical distribution 
of these molecules into labeled nociceptive lines is the necessary premise to get insight into their role in pain 
processing. 
3.1. Localization of BDNF and its Preferred Receptor TrkB in DRGs and Dorsal Horn of the Spinal Cord 
Early in situ hybridisation and immunohistochemical studies demonstrated the expression of BDNF mRNA and 
protein by a subpopulation of sensory neurons in DRGs, both in rodent and human tissues [50-52]. In mice and 
rats, BDNF positive DRG neurons are mainly small-to-medium- sized [53-55]. BDNF is localized in a population of 
peptidergic neurons expressing the calcitonin gene-related peptide (CGRP), which typically characterizes the 
nociceptors encoding thermal pain [56, 57]. Conversely, the neurotrophin is not expressed by non-peptidergic 
sensory neurons, that are identified by isolectin B4 (IB4), and represents a group of nociceptors principally 
involved in the transduction of mechanical pain [56, 57]. Accordingly, BDNF-positive fibres in the superficial 
dorsal horn overlap the localization of     CGRP-expressing fibres in lamina I and lamina II outer [55, 58]. 
Interestingly, BDNF has also been observed in sensory neurons that express neither CGRP nor IB4 [55]. 
Consistently, by using a BDNF-LAcZ reporter transgenic mouse, Basbaum’s group has recently demonstrated a 
broader expres- sion of BDNF than previously described [59]. In particular, these authors observed expression in 
large myelinated primary afferents, suggesting a still poorly understood role in the processing of non-nociceptive 






Fig. (1). Localization of BDNF and GDNF in the mouse DRGs and spinal dorsal horn. (A) Distribution of the 
two NFs in DRGs. Both BDNF (red) and GDNF (green) are expressed in small- to-medium primary sensory 
neurons, yet in distinct populations. 
(B) Distribution of BDNF (red) and GDNF (green) in the superficial dorsal horn. BDNF immunoreactive fibers are 
mainly localized  in laminae I-II outer, while GDNF immunoreactive fibers mainly end in lamina II. Abbreviations: 
LI = lamina I, LII = lamina II.  
 
The TrkB protein and mRNA are also expressed by DRG neurons of variable size in both rodents and humans [51, 
52, 54, 60], with a majority of medium-to-large-sized neurons [60]. By using transgenic TrkB
tauEGFP
, Li and 
colleagues [61] demonstrated a foremost expression of the BDNF receptor in Aδ low threshold mechanoreceptors, 
which heavily terminate in lamina III of the dorsal horn. On the other hand, we have previously shown that a subset 
of CGR P-positive nociceptors also co-express BDNF and TrkB, which suggests the existence of an autocrine 
activation loop at their peptidergic terminals [54]. 
BDNF and TrkB are also expressed by sparse propriospi nal neurons. In situ hybridization studies showed the 
expression of the BDNF mRNA in the deep dorsal horn of adult rats [52, 58]. Conversely, the receptor is expressed 
by the majority of neurons in the spinal cord [52, 62], including most ascending projection neurons in lamina I and 
in the deep dorsal horn laminae [62]. 
The expression of BDNF and TrkB in pain-related supraspinal centres has received less attention. However, 
few studies have demonstrated the involvement of the neurotrophin in different key areas for pain encoding, 
including the thalamus [63] and the parabrachial-amygdaloid pathways [64]. Previously, our group, in 
collaboration with Priestley’s group, demonstrated that BDNF is costored in individual dense-core vesicles (DCVs) 
with CGRP in the parabrachial projection to the amygdala [65]. 
3.2. Localization of GDNF and Its Preferred Receptor GFRα1/Ret in DRGs and the Dorsal Horn of the Spinal 
Cord 
As BDNF, GDNF is mainly expressed by small-to-medium-sized neurons in DRGs [55, 66, 67], although in a 
distinct and smaller population [55]. In mouse DRGs, GDNF is localized in a specific subgroup of peptidergic 
neurons containing CGRP and somatostatin [55]. The neurotrophic factor is anterogradely transported to the spinal 
dorsal horn, as suggested by immunohistochemical studies that localized the protein in the peptidergic afferent fibres 
within lamina I and lamina II outer [55, 68-70]. 
The mRNA of the GFL family receptor Ret is expressed by more than half of the lumbar DRG neurons in both 
the rat [66, 71-73] and mouse [74]. Most of the RET-expressing neurons also express the GDNF specific co-
receptor GFRα1: 66% in adult rats [73] and 89% in adult mice [75]. A similar expression pattern is also detected in 
the thoracic DRGs from adult humans, albeit in a sensibly lower percentage [51]. Interestingly, while GDNF is 
mainly expressed by the peptidergic neurons, the GFRα1/Ret receptor complex is typically found in the non-
peptidergic IB4-positive neurons, as well as in a small subset of non-peptidergic IB4-negative neurons [75, 76]. 
During development, Ret is up-regulated in non-peptidergic neurons, while TrkA is depleted; thus these neurons 
pass from NGF- to GDNF-dependence [75]. Ret expression in these sensory neurons is critical for their differ 
entiation and for the expression of several important molecules that are necessary for the detection of noxious 
stimuli [76, 77]. 
Consistently with the expression of GFRα1/Ret in non-peptidergic primary sensory neurons, GDNF receptors 
have been detected in primary afferent fibres in the dorsal horn, and, particularly, in the inner aspect of lamina II 
[70, 78]. Moreover, at the ultrastructural level, GFRα1 receptors are specifically expressed by IB4-positive terminals 
in the mouse spinal dorsal horn and are mainly localized ventrally to GDNF-expressing peptidergic terminals in 
lamina II [55, 70]. 
There is not compelling evidence of a propriospinal source of GDNF. Conversely, GFRα1/Ret are also expressed 
by some neurons in the dorsal horn, including putative projection neurons in lamina I that also express the subs tance 
P preferred receptor NK1 [78]. 
4. ROLE OF BDNF AND GDNF IN NOCICEPTION 
Although the localization of BDNF and GDNF and their receptors in primary sensory neurons strongly suggests 
 
 
an in- tervention in nociception, yet their significance in pain physiology remains elusive. The lack of specific 
pharmacological tools targeting the two molecules together with the difficulty to generate classical knockout 
animals due to the requirement of both factors for neuronal survival have for long hampered the investigation of the 
role of BDNF and GDNF in nociception. In recent times, however, the development and availability of conditional 
mutant mice in which the expression of specific molecules can be selectively depleted in mature neurons has opened 
new avenues to interrogate the contribution of the two NFs to pain transmission. 
Initial studies on the conditional blockade of a mutant TrkB receptor in mice led to conclude that BDNF does 
not contribute to acute heat, mechanical or chemical pain sensitivity [79]. More recently, Dembo and colleagues 
[59] have investigated the contribution of BDNF to nociceptive transmission by using a conditional transgenic 
mouse model in which BDNF can be selectively deleted in virtually all primary sensory neurons by tamoxifen 
injection. The ablation of BDNF produced only minor effects, including a slight increase in the heat threshold of 
male mice, but not females, to the tail immersion test and no effects on mechanical or cold sensitivity [59]. 
Consistently, it seems reasonable to infer that ongoing TrkB signaling facilitates the development of synaptic 
plasticity in the outer aspect of the superficial dorsal horn, where thermal input is mainly processed, while it has a 
minor impact deeper, where mechanical input is conveyed, thus making the system more prone to thermal sensiti 
zation [80]. 
A different scenario has been described when the GDNF receptor Ret was ablated from sensory neurons. By the 
con- ditional deletion of Ret in Nav1.8 expressing nociceptors in mice, Golden and colleagues [77] have 
demonstrated that the mutants express increased sensitivity to cold and increased formalin-induced pain, thus 
demonstrating a constitutive inhibitory role of Ret signaling in modulating nociception. These data are consistent 
with our findings ex vivo [70], demonstrating that GDNF, acting on the GFRα1 receptor complex, constitutively 
constrains the excitatory drive induced by afferent fiber activation upon spinal dorsal horn neurons (Fig. 2). 
While the role of BDNF and GNDF in the physiology of pain transmission is still debated, it is, on the other 
hand, well established that both NFs significantly contribute to the maladaptive changes occurring in pathological 
conditions, as it will be described in the following paragraphs. 
 
5. ROLE OF BDNF IN PATHOLOGICAL PAIN 
Several lines of evidence converge to indicate that BDNF principally acts as a pro-nociceptive modulator in 
sensory pathways, with a central role in the initiation and maintenance of inflammatory, chronic and/or neuropathic 
pain [81]. Nevertheless, a BDNF anti-nociceptive modulation has also been occasionally described, suggesting 
heterogeneity of BDNF actions that depend on the molecular pathways involved, the cells affected and the type of 
pathological condi tions (for review [5, 82-85]). In this section, we review the role of BDNF as a pain modulator 
emerging from different preclinical models of pathological pain. 
 
 
 Fig. (2). Effects of BDNF and GDNF on nociceptive transmission. The cartoon schematically illustrates the 
localization of BDNF (left) and GDNF (right) in spinal nociceptive pathways and their putative role in 
modulating nociceptive transmission. Left BDNF (green dots) is synthesized by peptidergic primary senso ry neurons 
in dorsal root ganglia and anterogradely transported to lamina I (LI) and outer lamina II (LIIo) of the dorsal horn via 
primary afferent C fibers (orange). BDNF acts both pre- and post-synaptically through its preferred receptor TrkB. 
Notably, BDNF+ peptidergic afferent fibers express pre-synaptic TrkB receptors, suggesting an autocrine function. 
BDNF/TrkB activation in superficial dorsal horn plays a major pro-nociceptive role by increasing lo cal network 
excitability. Right, another sub-population of peptidergic fibers (orange), distinct from that expressing BDNF, ends 
in lamina IIo and contains GDNF (red dots). Once released, GDNF activates the Ret/GFRα1 complex (in the 
 
diagram, only Ret is shown for simplicity), which is mainly expressed by non-peptidergic afferent terminals (blue) 
ending in inner lamina II (LIIi). GDNF, acting on pre-synaptic Ret/GFRα1, reduces the glutamate release associated 
with the activation of non-peptidergic fibers, thus limiting their associated excitatory drive. 
 
5.1. BDNF as Pro-nociceptive Neuromodulator in Inflammatory Pain 
BDNF expressed by the sensory neurons and released by their primary afferent fibers is necessary for the 
development of both formalin and carrageenan-induced inflammato ry pain [86]. The pro-nociceptive effect of 
BDNF in inflammatory pain has been typically associated with a pre- and post-synaptic potentiation of the 
glutamatergic neurotransmission in the spinal dorsal horn via NMDA receptor plastic ity. In carrageenan-treated rats, 
BDNF potentiates nociceptive spinal reflex activity and induces c-fos expression in dorsal horn neurons in NMDA 
receptor-dependent manner [87]. The BDNF-sequestering molecule trkB-IgG has also been observed to rescue 
hyperalgesic behavior and functional alterations [87]. Similarly, the co-administration of BDNF with the NMDA 
receptor antagonist D(-)-2-amino-5-phosphonovaleric acid (D-APV) prevents the BDNF-induced hy- peralgesia in 
mice [88]. NMDA potentiation is mediated through the activation of PKC and PLC-dependent pathways [89, 90]. 
BDNF may act pre-synaptically to induce hyperalgesic behavior. A pre-synaptic mechanism has been described 
in a rat model of inflammation based on subcutaneous injections of complete Freund’s adjuvant (CFA) [91]. The 
authors showed that BDNF increases the presynaptic release of gluta mate upon lamina II neurons. The effect was 
associated with increased synaptic input from large myelinated Aβ afferent fibers in lamina II, which typically 
encode light touch stimuli and thus may underlie allodynia in CFA rats [91]. 
More recently, the contribution of peripheral BDNF to in flammatory pain has been reconsidered in a conditional 
Advilin-CreERT2 knock-out mouse model, which lacks BDNF specifically in sensory neurons [59, 81]. Both 
studies observed a reduced nocifensive response in the second phase of the formalin test, which indicates a reduced 
central sensiti zation [59, 81], although the effect was observed only in males [59]. Surprisingly, however, Dembo 
and colleagues [59] did not detect any difference in the development of pain hypersensitivity in the CFA model of 
chronic inflammatory pain. On the other hand, Sikandar and colleagues [81] observed that BDNF deletion critically 
affects hyperalgesic priming, i.e. a neuroplastic mechanism producing a latent state of hyperresponsiveness in 
sensory neurons, which is thought to favor the transition from acute to chronic pain [81]. Hyperalgesic priming was 
induced by intraplantar injection of carrageenan and the effect was uncovered by prostaglandin E2 (PGE2) injection 
after six days. While primed control mice expressed long-lasting hyperalgesia following PGE2 injection, mice 
lacking BDNF in sensory neurons only exhibit a transient decrease of nociceptive thresholds [81]. 
5.2. BDNF as Pro-nociceptive Neuromodulator in Neuro pathic Pain 
BDNF also underlies the maladaptive plasticity occurring in neuropathic pain. Early studies in rats and mice 
with partial sciatic nerve lesion demonstrated that spinal BDNF contributes to the alterations resulting from the 
nerve damage in nociceptive pathways [92-95]. Systemic administration of either anti-BDNF or anti-TrkB 
neutralizing antibodies, Trk inhibitors or the BDNF scavenger TrkB/Fc abolishes behavioral pain hypersensitivity 
[92-94]. Upregulation of BDNF in sensory neurons and its central release upon spinal dorsal horn neurons have 
been observed in different nerve-injury models, including sciatic nerve transection, chronic constriction injury and 
nerve ligation [96-102]. 
A significant leap forward in understanding the role of BDNF in neuropathic pain was achieved with the study 
by Coull and colleagues [103]. The authors identified the spinal microglia as the main source of BDNF in nerve-
injured rats. In this model, the purinergic P2X4 receptors activate spinal microglia to trigger the release of BDNF, 
which, in turn, decreases KCC2 function, the main Cl
-
 extruder in lamina I projection neurons. The subsequent 
accumulation of Cl
-
 in these neurons reduces the strength of GABA/glycine ionotropic transmission, hence leading 
to hyperexcitability and pain hypersensitivity. These effects are recapitulated by intrathecal transfer of ATP-
stimulated microglia or by BDNF administration [103, 104], and are prevented by either de pleting BDNF in 
microglia [103, 105], blocking TrkB [103, 105], or knocking out P2X4 expression [105, 106]. 
BDNF also causes hyperexcitability of spinal neurons by increasing the NMDA receptor function, as reported in 
in- flammatory pain. Indeed, in rats with spinal nerve ligation, intrathecal injection of BDNF induces mechanical 
allodynia and long-term potentiation (LTP) via a mechanism involving the activation of NR2B-containing NMDA 
receptors [96, 107]. 
The concomitant alterations of inhibitory and excitatory transmission likely interact to sensitize central sensory 
neurons. Recent studies have specifically addressed this question. In particular, Hildebrand and colleagues [108] 
have reported that the downregulation of KCC2 induced by BDNF is both sufficient and necessary to promote 
NR2B-NMDA phosphorylation and LTP induction in lamina I neurons of nerve-injured rats. A key role in the 
signaling between BDN F-dependent Cl
-
 dysregulation and NMDA phosphorylation is played by STEP61 
phosphatase, whose down-regulation is coupled with KCC2 depletion and is sufficient to drive the potentiation of 
 
 
excitation [109]. Importantly, these mechanisms were also recapitulated in an ex-vivo spinal cord preparation 
obtained from human tissue, thus shortening the dis tance to clinical interventions [109]. 
Although the above-described mechanisms are based on post-synaptic alterations, pre-synaptic effects have also 
been reported. In mice with chronic constriction injury, BDNF in creased the expression of the Cl
-
 transporter 
NKCC1 in DRGs, thus causing an increase of intracellular Cl
-
, leading to transient presynaptic disinhibition and 
hypersensitivity [110]. The presynaptic effects are also likely mediated by microglial BDNF, which has been shown 
to act on afferent terminals for potentiating the NMDA-mediated responses [111]. Altogether, these data confirm the 
existence of coupling mechanisms involving Cl
-
 dysregulation and NMDA potentiation at both pre- and post-
synaptic levels, which     may be affected by BDNF. 
5.3. BDNF Involvement in other Forms of Chronic Pain 
Besides inflammatory and neuropathic pain, BDNF is involved in several other forms of chronic pain, including 
pain following spinal cord injury [34], trigeminal pain and migraine [112-114], opioid- and nicotine-induced 
hyperalgesia [105, 115], painful diabetic neuropathy [116, 117] and cancer pain [118-122]. Although these different 
models of pathological pain are based on distinct etiological grounds, yet pain hypersensitivity gated by BDNF is 
associated with the recurrent involvement of a restricted number of molecular actors, including P2X4 receptors, 
KCC2/NKCC1 transporters and NMDA receptors. Such commonality of mechanisms has important implications in 
conceiving new treatments for future therapeutic approaches, as later discussed in this review. 
5.4. BDNF as an Anti-nociceptive Neuromodulator 
While most published data indicate BDNF as a pain amplifier, yet other lines of evidence suggest that it may also 
ex ert anti-nociceptive effects. Early studies in the field showed that the central administration of BDNF may 
produce analgesic behavior. For instance, injections of BDNF into the rat midbrain caused thermal analgesia, likely 
acting on endogenous opioidergic/serotoninergic system [123]. Similarly, intracerebroventricular injections of 
BDNF in rats increased the latency of hind paw licking in the hot-plate test [124]. 
BDNF has also been reported to reverse established allodynic/hyperalgesic behaviors in animals with 
neuropathic pain clinical signs. Indeed, the administration of BDNF intrathecally [125] or through viral vectors 
[126] reverses ther mal and/or mechanical hypersensitivity following nerve injury. These anti-nociceptive effects of 
BDNF consistently rely on specific interactions between the trophic factor and synaptic inhibition mechanisms at 
both pre- and post-synaptic level. Pre-synaptically, TrkB activation stimulates the release of GABA from dorsal 
horn neurons upon primary affer ent terminals [125, 127], while post-synaptically, it enhances the spontaneous 
release of GABA and glycine upon lamina II neurons [128]. However, it should be stressed out that the 
comprehension of the mechanisms of action of BDNF (and other modulators) in the superficial dorsal horn is made 
difficult by the still disguised circuitry of this area of CNS. As an example, the observations by Bardoni and 
colleagues [128] regarding the enhancement of inhibitory neurotransmission in lamina II have been recently 
correlated with a polysynaptic chain consisting of a C peptidergic nociceptor, two islet cells in sequence, a central 
cell, a large vertical cell, and, eventually, a lamina I excitatory projection neuron [129]. As the first islet cell 
inhibits the second islet cell that, in sequence, is inhibitory to the central cell, the circuit is exc itatory onto the large 
vertical cell. Thus, this type of configu- ration can explain why BDNF was shown to produce ex vivo a depression of 
the evoked IPSCs as well as an increase of mIPSCs at synapses in the superficial dorsal horn [128]. 
Yet, the apparently contradictory co-existence of pro-nociceptive and anti-nociceptive effects is not surprising, 
as it belongs to the pleomorphic nature of BDNF. Recently, in fact, Huang and colleagues demonstrated that while 
the intrathecal administration of BDNF to the spinal cord of uninjured rats decreases KCC2, thus promoting 
disinhibition and hypersensitivity, nonetheless after spinal cord injury, the same BDNF treatment increases KCC2 
and restores synaptic inhibition [130]. Such dual behavior likely depends on the activation of specific intracellular 
pathways, as well as on the involvement of different cell types, thus highlighting that it is not possible to achieve 
efficacious BDNF-targeted phar macological solutions without an accurate understanding of the cellular and 
molecular actors and circuitries involved. 
6. ROLE OF GDNF IN PATHOLOGICAL PAIN 
GDNF displays both pro-nociceptive and anti-nociceptive functions in the sensory system, depending on the 
site of action and on the type of pain. While GDNF principally acts as an anti-nociceptive modulator in neuropathic 
pain, pro-nociceptive effects are often reported at the peripheral level and in experimental models of inflammatory 
pain (see for review [6, 12]). 
6.1. GDNF as an Anti-nociceptive Neuromodulator 
GDNF anti-nociceptive effects have been well estab lished in different models of neuropathic pain, including 
 
nerve-injury and diabetic neuropathy [131, 132]. 
In rats with sciatic nerve partial ligation or L5 spinal nerve ligation, intrathecal infusion of GDNF reverses 
mechanical and thermal hyperalgesia and GDNF pre-treatment avoids the insurgence of these neuropathic pain signs 
by preventing the alterations induced by nerve-injury on peripheral sodium channel subunits [12, 131]. Similarly, 
injections of viral vectors inducing the expression of GNDF [133-135] or of mesenchymal stem cells over-
expressing the trophic factor [136] alleviate the allodynic and hyperalgesic signs associated with a nerve injury in 
rodents. Specifically, intraspinal delivery of GDNF-expressing lentiviral vectors in rats prevented the up-regulation 
of the activating transcription factor 3 (ATF-3), a marker of nerve injury, as well as the down-regulation of the 
phenotypic marker of non-peptiderg ic nociceptors IB4 [134]. Injection of adenovirus vectors encoding GDNF 
attenuated allodynia and thermal hyperalgesia, reduced chronic constriction injury-induced neuronal apoptosis, 
inhibited microglia activation and cytokine production, indicating a neuroprotective action of the NF [133]. Similar 
effects have also been reported in mice [135]. Impor tantly, also human patients with neuropathic pain symptoms 
exhibit decreased levels of GDNF in their cerebrospinal fluid, thus reinforcing the clinical significance of the 
observations in animal models [137]. 
Different mechanisms have been proposed to underlie the anti-hyperalgesic effects of GDNF. GDNF released 
from peptidergic nociceptors may exert an inhibitory control on the glutamate excitatory drive from non-peptidergic 
fibres, with a subsequent reduction in neuronal activity [70]. Alternatively, GDNF may act on other targets, such as 
NCAM and other adhesion molecules, which concur to GDNF analgesic effects at the spinal level in a Ret-
independent manner [138-140]. In addition, GDNF and its receptors may alter pre-synaptically the neuronal 
excitability by directly acting on voltage-dependent channels. Indeed, a potentiation of the Kv4.1 potassium channel 
in the sensory neurons of nerve-injured animals has been recently described [141]. These inter actions may also 
require the modulation of other transmitters activating GPCRs that, in turn, reduce neuronal excitability and promote 
analgesia. In particular, intrathecal application of GDNF enhances the expression and the central release of the 
analgesic peptide somatostatin, suggesting a GD NF anti-allodynic effect via somatostatinergic mechanisms [142, 
143]. 
Monoamines are another group of analgesic transmitters that have been associated with the GDNF analgesic 
effects. Indeed, injection of GDNF into the locus coeruleus of nerve-injured rats exerted prolonged analgesia by 
enhancing the descending noradrenergic inhibition to spinal dorsal horn neurons via α2-adrenoceptor [144]. 
Little is known, however, regarding the signaling pathways through which GDNF and its receptors produce 
analgesia. In spinal dorsal horn neurons, GDNF administration to nerve-injured rodents leads to the down-regulation 
of different intracellular pathways associated with pain hypersensitiv ity, such as nectin-1/c-Src [138] and integrin 
β1/FAK [145], or the up-regulation of anti-nociceptive pathways, such as E- cadherin/p120 catenin [146]. 
6.2. GDNF as a Pro-nociceptive Neuromodulator 
While GDNF is frankly anti-nociceptive in neuropathic pain, it has more prominent pro-nociceptive functions in 
in- flammatory pain. Ogun-Muyiwa and colleagues [147] observed that exogenous GDNF up-regulates pro-
nociceptive mediators, such as substance P, in adult rat DRG cultures. The pronociceptive role was subsequently 
confirmed by direct intraplantar injection of GDNF, which enhances both thermal sensitivity mediated by the 
thermal transducer TRPV1 [148] and mechanical sensitivity associated with IB4-positive nociceptors [149, 150]. 
As IB4-positive neurons are known to express GFRα/Ret receptor complex, these sensory neurons are the more 
obvious target for GDNF-dependent  sensitization. Indeed, ablating IB4-positive nociceptors prevent GDNF-
induced mechanical hyperalgesia [149]. In the same study, Bogen and colleagues were able to reverse the GDNF-
dependent hyperalgesia by interfering with several ki nases downstream to GFRα/Ret, including PLCγ, MAP- 
K/ERK, PI3K, CDK5 and Src family kinase. 
The effect of GDNF on IB4-positive neurons is not only limited to nociceptor sensitization but also extends to 
hyper- algesic priming [151, 152]. GDNF induces priming in IB4- positive neurons via PKCε signaling pathway [ 
151] and priming is directly associated with a reduction in the levels of the GPCR kinase 2 (GRK2) [152]. 
The involvement of GDNF in the development of inflam matory pain has been described in different chronic 
pain models, such as CFA-induced inflammation [153, 154]. In rats with CFA-induced arthritis, GDNF stored in 
DRGs is de pleted and the intrathecal injection of a function-blocking antibody against GDNF decreases the 
inflammatory hyperal gesia [153]. GDNF, as well as other related GFLs (in particu lar artemin), have also been 
involved in several other models of inflammatory pain, including bone inflammation [155] and cystitis [156, 
157]. 
7. INTERPLAY BETWEEN GDNF AND BDNF IN NO CICEPTIVE PATHWAYS 
In the previous sections, we have explored in-depth the current knowledge on the role of BDNF and GDNF in the 
control of nociceptive neurotransmission under normal and pathological conditions. Interestingly, several distinctive 
 
 
and somehow complementary features characterized the localiza tion of these two NFs in nociceptive pathways (Fig. 
2). Specifically: 1- BDNF and GDNF are basically expressed by two distinct populations of peptidergic nociceptors 
[55]; 2- In DRGs, BDNF is mainly expressed by the same neurons expressing its cognate receptor TrkB, suggesting 
an autocrine function [5, 54], while the GDNF receptor complex (GFRα-Ret) is expressed by the non-peptidergic 
sensory neurons [66, 70]; 3- while clearly pro-nociceptive and anti-no ciceptive effects cannot be univocally 
associated to one trophic factor or the other, yet a general consensus supports the concept that in neuropathic pain, 
BDNF is pro-nociceptive, while GDNF is anti-nociceptive [5, 6, 129]. 
 
Table 1. BDNF and GDNF levels in neurological disorders. 
 
Disease Model BDNF GDNF 
Spinal cord 
ischemia 
Rat model of transient ischemia 
[158] 
↑ in spinal neurons ↑in spinal neurons and 
astrocytes 
Parkinson’s disease Lesion of the rat nigrostriatal pathway 
by 6-hydroxy- dopamine 
[159] 
↑ in striatum and 
midbrain of young rats 
↓ in striatum and ↑ in 
midbrain of old rats 
↑ in striatum and ↔ in 
midbrain of young rats 
↔ in striatum and 
midbrain of old rats 
Alzheimer’s 
disease 
B6C3-Tg transgenic mouse 
[160] 




Pneumococcal meningitis in rat 
[161] 
↓in hippocampus ↓in hippocampus 
Alcohol spectrum 
disorder 
Ethanol administration to 
postnatal rats [162] 
↑ in amygdala and ↔ in 
pyriform cortex in 
P7 rats 
↓ in amygdala and ↓in 
pyriform cor tex 
in P15 rats 
↑in amygdala and ↑ in 
pyriform cor tex in P7 rats 
↑ amygdala and 
↓pyriform cortex in P15 
rats 
Hyperoxia Exposure of P7-12 rats to the 
hyperoxic condition 
[163] 
↓mRNA in prefrontal 
cortex and ↑ in 
isocortex 
↑ mRNA in prefrontal 
cortex and ↑ in 
isocortex 
Several works in the last years have explored how patho logical conditions affect BDNF and GDNF expression in 
CNS, thus demonstrating the implications of both factors in the shift from normality to an altered neurological 
situation Table (1). In several cases, the levels of the two NFs are regulated in an opposing direction, reinforcing the 
hypothesis that they play alternative/complementary roles. 
However, only a few studies have properly addressed whether BDNF and GDNF directly interact in modulating 
the function of central neurons. For instance, Giehl and colleagues [164] showed that GDNF prevents the 
degeneration of lesioned corticospinal neurons via BDNF signaling. Similarly, combined administration of GDNF 
and BDNF, but not each factor individually, favors motor neuron differentiation in vitro [165] and improves motor 
dysfunction in a rat model of spinal cord injury [166]. An interaction between GDNF and BDNF was also observed 
in the hippocampus in 3xTg-AD mice that modeled Alzheimer’s disease [167]. Here, the over-expression of GDNF 
improved cognition performances and increased BDNF expression. 
Importantly, imbalances in the expression of BDNF and GDNF are associated with several neurological 
alterations in humans. Aged subjects exhibiting cognitive decline or with mild Alzheimer’s disease display decreased 
BDNF and GDNF serum levels when compared with healthy subjects [168]. A significant decrease in both NFs has 
also been reported in patients with schizophrenia [169]. Conversely, in patients diagnosed with bipolar disorder 
where only BDNF was decreased, lithium-based therapy inverted the ratio of circulating BDNF/GDNF, suggesting 
that the reciprocal lev els determine the overall effect on the nervous system [170]. 
8. THERAPEUTIC PERSPECTIVES 
Given the part played by BDNF and GDNF in pain mod- ulation preclinically, the two molecules certainly 
represent an attractive target for the development of novel therapeutic strategies. Several approaches have been 
proposed in animal studies, particularly for the treatment of neuropathic pain in which, as highlighted above, BDNF 
and GDNF have opposite effects. 
8.1. Targeting BDNF/TrkB 
 
The main approaches derived from preclinical studies to treat pain by blocking BDNF/TrkB signaling can be 
distinct in: i) scavenging BDNF, ii) targeting the extracellular TrkB domain, iii) interfering with the intracellular 
kinase domain. 
i- Scavenging BDNF 
Scavenging BDNF can be achieved in vivo by delivering a TrkB-Fc fusion protein, obtained from the 
extracellular do main of TrkB and the Fc domain of human IgGs [171]. This approach has been extensively used to 
probe the role of endogenous BDNF in pain models, including nerve injury [103], diabetic neuropathy [172], and 
pain incision model [173]. Although highly specific, the method is poorly translatable in clinical settings since the 
scavenger needs to be ap plied intrathecally or locally at the central sites where BDNF is released. 
ii- Targeting the Extracellular TrkB Domain 
Targeting the extracellular domain, thus reducing the probability of ligand binding, can be achieved either 
through TrkB blocking antibodies [174] or by developing new recep tor antagonists [175]. Monoclonal function-
blocking antibodies against TrkB receptors have been successfully employed in preclinical investigations (i.e., 
mouse clone 47 [176],), and proved to be effective in blocking the effects of BDNF on neuronal activity in acute 
spinal cord slices [177], as well as in reversing neuropathic [103] and other forms of pathological [105] pain in 
rodents. Similarly to TrkB-Fc, sys temically administered anti-trkB blocking antibodies do not reach the CNS, 
which, together with the relatively low sensi tivity [176], makes them poor candidates for clinical treatments. In the 
last decade, the identification of novel small molecules acting as negative allosteric modulators of TrkB receptors 
has brought important advances in pharmacokinetics and drug bioavailability. By using a peptidomimetic 
approach, Cazorla and colleagues identified a small BDNF fragment, cyclotraxin-B, which allosterically alters the 
conformation of TrkB [178]. Cyclotraxin-B was thereafter proved to have clear antinociceptive effects in different 
pain models, including post-stroke pain [63], nerve ligation injury [113], and inflammatory pain [179]. On the other 
hand, cyclotraxin-B does not only act on the BDNF dependent mechanisms but also ont the BDNF independent 
forms of TrkB activation, which raises the issue of the specificity of the effect. Moreover, the peptide is effective if 
delivered intravenously, but not orally. These limitations have been over come by the same group through the 
identification of ANA-12, a non-peptidic small molecule [175]. ANA-12 allosterically prevents BDNF from 
binding TrkB with nanomolar potency [175] and, unlike cyclotraxin-B, can be delivered orally, thus representing a 
promising and specific approach for clinical trials. Very promising, an increasing num ber of preclinical studies have 
confirmed the antinociceptive efficacy of ANA-12 in different pain models, including nerve injury [111], 
inflammatory pain [180], trigeminal pain [114] and migraine [112, 181]. Recently, ANA-12 has also been 
documented to counteract chronic hypersensitivity due to visceral pain in cyclophosphamide-induced cystitis [182] 
and in a model of irritable bowel syndrome induced by maternal separation in rats [183]. 
iii- Interfering with the Itracellular Kinase Domain 
The main approach to intracellularly block tyrosine kinases activity is to interfere with the ATP binding site of 
the enzymes [184, 185]. The indolocarbazole K252a is one of the first used compounds acting as a competitive 
inhibitor of the ATP site, thus blocking Trk catalytic activity [186, 187]. K252a administration effectively blocks the 
rise of intracellu lar Ca
2+
 promoted by BDNF in acute slices of the rat superfi cial dorsal horn [177] and, in vivo, it 
reduces hypersensitivity in visceral [188, 189], neuropathic [103, 190], inflammatory [191], and skeletal pain [192]. 
Encouraged by preclinical studies, different pharmaceuti cal companies have invested considerable resources in 
im proving kinases inhibitors, some of which are currently under clinical trials or investigations for a broad range of 
diseases, including oncological disorders and pain (for review [184, 193-196]). Although most of them exhibit high 
potency in vitro, yet the development of a TrkB inhibitor as a mar keted product has not been successful at present. 
Unfortunately, developing tyrosine kinase antagonists for specific Trk receptors is challenging since ATP 
competitive Trk inhibitors are at best Trk specific (pan-Trk inhibitors) but can hardly discriminate between Trk 
subtypes [184]. Therefore, a major limitation concerning the use of these molecules is the risk to develop central side 
effects. To limit adverse effects, several attempts have been made to develop molecules that do not cross the blood-
brain barrier (BBB) but mainly act at the periphery. Some of these molecules, e.g., ARRY-470 [197] or PF-
06273340A [198], exhibit antinociceptive effects in animal models of chronic pain. In a recent ran- domized, double-
blinded clinical trial, the pan-Trk inhibitor ONO-4474 was proved to be analgesic in patients with moderate to severe 
osteoarthritis [199]. Yet, it is likely that all these molecules also target peripheral Trk receptors other than TrkB (e.g., 
TrkA). 
 
8.2. Alternative Targets to Counteract BDNF Pronocicetive Effects 
Due to the above-described limitations, to date, there are no effective pain treatments based on BDNF/TrkB. The 
critical role played by BDNF and TrkB receptors in the survival of central neurons further limits the use of TrkB 
antagonists as a safe therapeutic approach. Moreover, the complexity and plurality of the intracellular signaling 
 
 
pathways activated by tyrosine kinase receptors make it difficult to develop selective pharmacological treatments. 
Targeting BDNF/TrkB can lead to both on-target side effects, due to the inactivation of BDNF-dependent pathways 
important for the normal functioning of the healthy nervous system, and off- target side effects, due to the lack of 
specificity and the interaction with relevant non-BDNF pathways [200]. 
Other viable therapeutic options to counteract TrkB-dependent pathological alterations can be achieved by targeting 
upstream or downstream effectors. 
Upstream targeting of microglia can effectively reduce the BDNF-dependent alterations in neuropathic pain [201]. In 
this respect, microglial P2X4 receptors, whose activation is necessary for the subsequent release of BDNF, are viable 
targets for clinical interventions [202]. Alternatively, several GPCR receptors, such as dopamine receptor 1 (D1R 
[203]), PACAP receptor [23], adenosine A2 receptor [204] and the cannabinoid receptor 1 [205], can transactivate 
TrkB, thus representing alternative targets to reduce TrkB signaling. 
Among downstream signaling pathways, a key mechanism underlying TrkB-dependent pain hypersensitivity, acts 
through the downregulation of KCC2, which causes an imbalance between excitatory and inhibitory 
neurotransmission [103]. KCC2 itself represents a putative pharmacological target [206]. Therefore, the development 
of KCC2 enhancers is a promising therapeutic avenue to restore inhibition and counteract the symptoms associated 
with the BDNF-TrkB-KCC2 cascade [207]. 
8.3. Targeting GDNF/GFRα1/Ret 
Although GDNF and its receptor, as well as other GFLs, have been shown to either increase or decrease sensitivity in 
different preclinical models of pain, the antinociceptive role of GDNF in neuropathic pain has been consistently 
reported (for review, see [6]). Thus, potentiating the GDNF system is, theoretically, a viable strategy to counteract 
neuropathic pain symptoms. To achieve this goal, the following strate gies have been explored: i) direct 
administration of GDNF; ii) synthesis and delivery of small molecule agonists; iii) alternative druggable targets to 
potentiate GDNF/GFRα1/Ret pathways. 
 
i)- Administration of GDNF 
In different experimental neuropathic pain models, the antinociceptive effects of GDNF have been demonstrated 
by the direct administration of GDNF, mostly intrathecally [131, 142, 143, 208]. In terms of translatability into 
clinical settings, however, intrathecal administration of GDNF is hampered by the invasiveness of the procedure and 
potential side effects [209]. On the other hand, the poor CNS bioavailability of proteinaceous molecules with high 
molecular weight, such as the NFs, strongly limits the use of systemic administration in clinical interventions [210, 
211]. Many efforts have been made to overcome the BBB obstacle and im prove GDNF availability to the nervous 
tissue, for instance, by intranasal administration using cationic liposomes [212, 213] or by encapsulating GDNF in 
microspheres, allowing a slower release when centrally injected [214-216]. 
Gene-transfer approaches represent a more effective way to deliver GDNF in the CNS. These approaches can be 
either implemented by trojan horses, such as liposomes, that carry GDNF-encoding plasmids across the BBB to the 
central neurons [217], or by gene transfer with recombinant viral vectors locally infecting the target neurons [210]. 
A num ber of viral vectors carrying the gdnf gene have been developed, in particular, for rescuing motor performance 
in animal models of Parkinson’s disease [210]. These include the herpes simplex virus (HSV [218]), lentiviruses 
[219], adenoviruses [220] and adeno-associated viruses (AVV [221-223]). Vector-mediated GDNF delivery has also 
been proposed to reverse neuropathic pain symptoms after nerve injury, either by spinal injection of lentiviral 
vectors [134, 135], intracutaneous inoculation of engineered herpes simplex virus [224] or intramuscular injection of 
recombinant adenovirus [133, 225]. 
Eventually, cell therapy represents another putative strategy to deliver GDNF to central neurons. Administration 
of astrocytes, macrophages and neural stem cells engineered to express GDNF, or carotid bulb cells, an endogenous 
source of GDNF, have been successfully employed to prevent cell loss in certain neurodegenerative diseases 
[226-228]. The use of GDNF-based cell therapy has also been successfully adopted for the treatment of pain 
hypersensitivity in nerve-injured rats [229]. 
Clinical trials to test the effectiveness of GDNF-based therapies in humans have so far largely failed, and more 
im- portantly, have unveiled the main limitations of this ap proach: first, the onset of unwanted side effects, such as 
nau sea, weight loss, anorexia; second, the inadequate concentration reached by GDNF in target tissues; and third, 
the production of neutralizing anti-GDNF antibodies in a number of patients [230, 231]. Gene therapy may 
represent an improvement as compared to the direct administration of the NF, as demonstrated in preclinical 
investigations. A large clinical trial is currently ongoing to address the effectiveness of AAV-gdnf administration in 
the putamen of patients with Parkinson’s disease [232], which may subsequently open the avenue for similar 
approaches for the treatment of neuropath ic pain. Indeed, GDNF has not yet been employed to treat neuropathic 
pain in humans. Artemin, instead, has already been tested in two clinical studies in patients with sciatica, with the 
main purpose to verify the safety, tolerability, and pharmacokinetics of the NF [233, 234]. 
 
ii- Small Molecule Agonists 
To overcome the BBB, another viable strategy is the syn thesis of non-peptidyl small molecule agonists 
activating GDNF receptors complex GFRα1/Ret. The first described agonist of GFRα1 was XIB4035 [235]. Local 
XIB4035 administration was shown to alleviate the symptoms of diabetic neuropathy [132]. More recently, 
Sidorova and colleagues [236] identified by high-throughput screening, a novel Ret agonist, named BT13. This 
molecule directly modulates RET and its downstream intracellular signaling cascades. BT13 systemic 
administration reverses nerve injury-induced alterations in sensory neurons [236]. 
iii- Alternative Druggable Targets to Potentiate GDNF/GFRα1/Ret Pathways 
Emerging evidence suggests that the activation of the in tracellular Ret signaling cascade is the endpoint of a 
complex and multifaceted ensemble of interacting factors, among which GFLs and GFRs likely represent a 
necessary but not sufficient component. Understanding the specific rel evance and involvement of these interacting 
factors may pro vide novel approaches to restore pharmacologically Ret signaling in pathological settings. 
The molecular composition of the membrane microdomains (lipid rafts) in which the GFRs are anchored 
represents a key factor influencing intracellular Ret signaling pathways [44]. Indeed, GDNF-mediated activation of 
GFRα1 fosters the recruitment of Ret to lipid rafts, thus favoring Ret/Src kinases coupling [44]. The interaction of 
GFRα1 and Ret outside lipid rafts microdomains does not preclude Ret activation but attenuates downstream 
functional effects [237]. GM1 ganglioside is an important component of lipid rafts and displays neurotrophic 
actions in vitro and in vivo [238, 239]. A recent study showed that the administration of GM1 promotes Ret 
phosphorylation by enhancing the interaction between GDNF and GFRα1 [239]. Interestingly, the administration 
of GM1 to patients with post-herpetic neuralgia or spinal cord injury was found to sensibly reduce pain severity 
[240]. 
Transcription factors represent other alternative targets for indirectly manipulating the Ret function. 
Specifically, the transcription factor nurr1 has been shown to stimulate Ret tyrosine kinase activity in animal 
models of Parkinson’s disease [241, 242]. Pharmacologically, nurr1 can be targeted by delivering bexarotene, an 
agonist of retinoic X receptors, which in turn forms heterodimers with the transcription factor [242]. Interestingly, 
bexarotene also exerts antinociceptive effects in neuropathic pain by counteracting certain spinal 
neuroinflammatory processes [243], thus leaving open the possibility that nurr1-Ret pathways may also be targeted 
in the spinal cord. 
Eventually, as reported earlier, GDNF may exert antinociceptive effects, also acting upon receptors other than 
Ret. In particular, adhesion molecules such as NCAM, E-cadherin and nectin-1 have been implicated in GDNF 
antinociceptive signaling pathways [49, 138, 140]. Importantly, C3D, a NCAM mimetic peptide, recapitulates the 




While pre-clinical studies in the last 20 years have consistently reported that BDNF and GDNF play a significant 
role in the development of pain hypersensitivity, no novel pharmacological strategies have been successfully 
developed based on this knowledge. The reasons are multiple (see for review [244, 245]), and include the difficulty 
to correctly dose and deliver the treatments, as well as the necessity to deal with advanced stages of the pathology 
in humans. On the mechanistic side, however, one major obstacle is the tremendous fluidity of NFs activity. As 
discussed in this review, the same NFs can generate opposite effects by activating different intracellular pathways 
or different receptors; not to say that the same molecules have short- and medium- term effects on neuronal 
function, but also long term trophic effects on neuronal survival and differentiation. Therefore, the identification of 
specific downstream targets in Ret- and TrkB- dependent pathways involved in the onset of pain symptoms (or in 
their reduction) is probably a more viable and safer strategy rather than directly tackling NFs receptors. In this 
respect, defining the mechanistic ground through which NFs promote sensitization in pathological pain is necessary 
to refine pharmacological interventions, reduce side effects and increase effectiveness. Additionally, more efforts 
are needed to be made not only in the analysis of the effects of individual relevant factors but also in their 
reciprocal interactions. In this review, we showed that BDNF and GDNF exert distinct complementary effects in 
pain processing. Their reciprocal contribution appears particularly evident in neuropathic pain, where BDNF/TrkB 
signaling plays a dominant pro-nociceptive role, while GDNF/GFRα1/Ret signaling mainly exerts anti-nociceptive 
effects. 
Any imbalance in their contribution to the modulation of pain processing may concur with the development of 
pathological conditions. Although we are still far from understanding properly the circuitry that triggers the 
opposing effects of BDNF and GDNF in the initial process of nociceptive stimuli [129], this dual mechanism of 
action provides, at least theoretically, the possibility to pharmacologically modulate its final outcome by the 
combinatory use of agonist (mimetic) and antagonist (lytic) drugs to each NF in a fashion similar to that currently 
 
 
in use in the pharmacological control of sympathetic and parasympathetic visceral neurotransmission. It is at 
present difficult to foresee which could be the advantages or disadvantages of such an approach. If indeed, it will 
be possible to develop adequate pharmacological tools that overcome the limitations described in the previous 
section of this paper, however, one has to keep in mind that any drug acting on either of the two NFs will influence 
their relative functional balance. Thus, it might be speculated that, for e.g., the development of a GDNF agonist 
would be equally effective than that of a BDNFantagonist in the control of pathological pain. In the transition from 
preclinical studies to therapeutic intervention, the interactions between the two NFs should be taken into 
consideration. Most of the clinical trials in the past were focused on single targets, with the idea that a single 
molecule or receptor can effectively restore a pathological condition. The interactions of BDNF and GDNF in 
nociceptive pathways impose a change of approach toward combinational therapies [246], including the delivery of 
both trophic factors and/or small molecules acting on downstream targets, aiming to restore an altered balance. On 
the other hand, the successful development of combinational therapies based on a homeostatic approach implies the 
availability of diagnostic tools to non-invasively explore the neurotrophic content at both central and peripheral 
levels in different types of painful neuropathies [247-249]. 
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